326 related articles for article (PubMed ID: 16456079)
1. Structure of human urokinase plasminogen activator in complex with its receptor.
Huai Q; Mazar AP; Kuo A; Parry GC; Shaw DE; Callahan J; Li Y; Yuan C; Bian C; Chen L; Furie B; Furie BC; Cines DB; Huang M
Science; 2006 Feb; 311(5761):656-9. PubMed ID: 16456079
[TBL] [Abstract][Full Text] [Related]
2. Structural basis of interaction between urokinase-type plasminogen activator and its receptor.
Barinka C; Parry G; Callahan J; Shaw DE; Kuo A; Bdeir K; Cines DB; Mazar A; Lubkowski J
J Mol Biol; 2006 Oct; 363(2):482-95. PubMed ID: 16979660
[TBL] [Abstract][Full Text] [Related]
3. Crystal structures of two human vitronectin, urokinase and urokinase receptor complexes.
Huai Q; Zhou A; Lin L; Mazar AP; Parry GC; Callahan J; Shaw DE; Furie B; Furie BC; Huang M
Nat Struct Mol Biol; 2008 Apr; 15(4):422-3. PubMed ID: 18376415
[TBL] [Abstract][Full Text] [Related]
4. Does the urokinase receptor exist in a latent form?
Yuan C; Huang M
Cell Mol Life Sci; 2007 May; 64(9):1033-7. PubMed ID: 17372678
[TBL] [Abstract][Full Text] [Related]
5. Crystallization of soluble urokinase receptor (suPAR) in complex with urokinase amino-terminal fragment (1-143).
Huang M; Mazar AP; Parry G; Higazi AA; Kuo A; Cines DB
Acta Crystallogr D Biol Crystallogr; 2005 Jun; 61(Pt 6):697-700. PubMed ID: 15930623
[TBL] [Abstract][Full Text] [Related]
6. Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide.
Llinas P; Le Du MH; Gårdsvoll H; Danø K; Ploug M; Gilquin B; Stura EA; Ménez A
EMBO J; 2005 May; 24(9):1655-63. PubMed ID: 15861141
[TBL] [Abstract][Full Text] [Related]
7. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
[TBL] [Abstract][Full Text] [Related]
8. Crystal structure of the urokinase receptor in a ligand-free form.
Xu X; Gårdsvoll H; Yuan C; Lin L; Ploug M; Huang M
J Mol Biol; 2012 Mar; 416(5):629-41. PubMed ID: 22285761
[TBL] [Abstract][Full Text] [Related]
9. Interaction between kringle and growth-factor-like domains in the urokinase molecule: possible role in stimulation of chemotaxis.
Stepanova VV; Beloglazova IB; Gursky YG; Bibilashvily RS; Parfyonova YV; Tkachuk VA
Biochemistry (Mosc); 2008 Mar; 73(3):252-60. PubMed ID: 18393759
[TBL] [Abstract][Full Text] [Related]
10. Structural analysis of the interaction between urokinase-type plasminogen activator and its receptor: a potential target for anti-invasive cancer therapy.
Ploug M; Gårdsvoll H; Jørgensen TJ; Lønborg Hansen L; Danø K
Biochem Soc Trans; 2002 Apr; 30(2):177-83. PubMed ID: 12023847
[TBL] [Abstract][Full Text] [Related]
11. Identification of specific sites involved in ligand binding by photoaffinity labeling of the receptor for the urokinase-type plasminogen activator. Residues located at equivalent positions in uPAR domains I and III participate in the assembly of a composite ligand-binding site.
Ploug M
Biochemistry; 1998 Nov; 37(47):16494-505. PubMed ID: 9843416
[TBL] [Abstract][Full Text] [Related]
12. Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo.
Pass J; Jögi A; Lund IK; Rønø B; Rasch MG; Gårdsvoll H; Lund LR; Ploug M; Rømer J; Danø K; Høyer-Hansen G
Thromb Haemost; 2007 Jun; 97(6):1013-22. PubMed ID: 17549305
[TBL] [Abstract][Full Text] [Related]
13. Differential inhibition of endothelial cell proliferation and migration by urokinase subdomains: amino-terminal fragment and kringle domain.
Kim KS; Hong YK; Lee Y; Shin JY; Chang SI; Chung SI; Joe Y
Exp Mol Med; 2003 Dec; 35(6):578-85. PubMed ID: 14749538
[TBL] [Abstract][Full Text] [Related]
14. Geometry of GPPE binding to picrate and to the urokinase type plasminogen activator.
Zesławska E; Stürzebecher J; Oleksyn BJ
Bioorg Med Chem Lett; 2007 Nov; 17(22):6212-5. PubMed ID: 17905583
[TBL] [Abstract][Full Text] [Related]
15. Urokinase-type plasminogen activator.
Crippa MP
Int J Biochem Cell Biol; 2007; 39(4):690-4. PubMed ID: 17118695
[TBL] [Abstract][Full Text] [Related]
16. The effects of amino-acid mutations on specific interactions between urokinase-type plasminogen activator and its receptor: Ab initio molecular orbital calculations.
Tsuji S; Kasumi T; Nagase K; Yoshikawa E; Kobayashi H; Kurita N
J Mol Graph Model; 2011 Aug; 29(8):975-84. PubMed ID: 21605990
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of the enzymatic activity of single-chain urokinase plasminogen activator by soluble urokinase receptor.
Higazi A; Cohen RL; Henkin J; Kniss D; Schwartz BS; Cines DB
J Biol Chem; 1995 Jul; 270(29):17375-80. PubMed ID: 7615542
[TBL] [Abstract][Full Text] [Related]
18. A soluble, ligand binding mutant of the human urokinase plasminogen activator receptor.
Masucci MT; Pedersen N; Blasi F
J Biol Chem; 1991 May; 266(14):8655-8. PubMed ID: 1851152
[TBL] [Abstract][Full Text] [Related]
19. Structural investigations of recombinant urokinase growth factor-like domain.
Beloglazova IB; Beabealashvilli RSh; Gursky YG; Bocharov EV; Mineev KS; Parfenova EV; Tkachuk VA
Biochemistry (Mosc); 2013 May; 78(5):517-30. PubMed ID: 23848154
[TBL] [Abstract][Full Text] [Related]
20. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes.
Stoppelli MP; Corti A; Soffientini A; Cassani G; Blasi F; Assoian RK
Proc Natl Acad Sci U S A; 1985 Aug; 82(15):4939-43. PubMed ID: 2991901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
